Autologous organoids and T cell co-cultures as a powerful personalized platform for immunotherapy
Cancer immunotherapies have shown substantial success as a treatment strategy to combat cancer. However, their efficacy is limited to only a subset of patients. Treatment failure can be attributed to the high degree of heterogeneity in patient tumors and immunosuppressive tumor features, which are both critical aspects that need to be recapitulated in preclinical models used for the development of novel immunotherapeutics.
Download this poster to discover:
- How autologous HUB Organoids® T cell co-cultures serve as a patient-relevant in vitro platform to test effective immunotherapies
- Our protocols for generating biobanks of both normal and colorectal cancer (CRC) organoids paired with tumor-infiltrating lymphocytes (TILs)
- How to enrich your culture for tumor-reactive TILs and their application to tumor-specific killing